In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna Inc.

www.modernatx.com

Latest From Moderna Inc.

Internal Manufacturing Capabilities Are Critical To Level-Up eTheRNA

A year into his role as a CEO of the Belgian mRNA biotech eTheRNA immunotherapies, industry veteran Steven Powell talks to In Vivo about his plans for the business over the coming couple of years. An important timeframe to move the company well into clinical activity.

BioPharmaceutical Research and Development Strategies

IPO Year In Review: Late Rally Gives 50 Newly Public Biopharma Firms A 45.1% Average Return

First-time offerings by drug developers fell from 2018 when 67 launched, but IPO investors’ fortunes improved with a year-end rally providing a 45.1% return versus a 7.5% loss in the prior year.

Financing Deals

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.

C-Suite Speaks Outlook 2020

Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials

As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.

Advisory Committees Vaccines
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • Moderna Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Moderna Inc.
  • Senior Management
  • Stephane Bancel, CEO
    Lorence Kim, CFO
    Stephen Hoge, MD, Pres.
    Tal Zaks, MD, PhD, CMO
  • Contact Info
  • Moderna Inc.
    Phone: (617) 714-6500
    200 Technology Square
    Cambridge, MA 02139
    USA
UsernamePublicRestriction

Register